Basic Needs and Higher Pursuit of Postoperative Adjuvant Endocrine Therapy in Patients with Primary Breast Cancer——A Comment on the International Clinical IES-031 Research Results with Exemestane
1Early Breast Cancer Trialists'Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials [J]. Lancet, 1998, 351:1451.
4Coombes RC,Hall E,Gibson LJ,et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer [J]. N Engl J Med, 2004, 350(11):1081-1092.
5Baum M, Buzdar AU, Cuzik J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer:first results of the ATAC randomised trial [J]. Lancet, 2002,359(9324) :2131-2139.
6Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer [J]. N Engl J Med, 2003,349(19): 1793-1802.
7[1]Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet, 1998,351:1451～1467
8[2]Love RR, Barden HS, Mazess RB, et al. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Inter Med, 1994,154:2585～2588
9[3]Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast - cancer prevention trials. Lancet, 2003,361:296～300
10[4]Osborne CK, Schiff R. Growth factor receptor cross - talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast, 2003,12: 362～367
